Australian cases show favourable outcomes for tocilizumab use early in COVID-19 disease

Australian patients with severe COVID‐19 pneumonia treated with tocilizumab have had favourable clinical outcomes, a small case series shows. The positive findings make a case for tocilizumab be included in randomised controlled trials of treatment for patients with severe COVID‐19 pneumonia, and for it to be considered for compassionate use  pending the results of these ...

Already a member?

Login to keep reading.

© 2021 the limbic